Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Mereo BioPharma Group (MREO) stocks in Canada

Learn how to easily invest in Mereo BioPharma Group stocks.

Mereo BioPharma Group is a biotechnology business based in the US. Mereo BioPharma Group stocks (MREO.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.15 – a decrease of 11.89% over the previous week. Mereo BioPharma Group employs 38 staff and has a trailing 12-month revenue of around $36.5 million.

How to buy shares in Mereo BioPharma Group

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MREO – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Mereo BioPharma Group stock price (NASDAQ:MREO)

Use our graph to track the performance of MREO stocks over time.

Mereo BioPharma Group shares at a glance

Information last updated 2022-01-17.
Latest market close$1.26
52-week range$1.27 - $4.71
50-day moving average $1.78
200-day moving average $2.60
Wall St. target price$699.23
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.36

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
FREE TRADES
Wealthsimple Trade
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99 - $9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy Mereo BioPharma Group stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Mereo BioPharma Group price performance over time

Historical closes compared with the close of $1.26 from 2022-01-19

1 week (2022-01-14) -11.89%
1 month (2021-12-17) -26.32%
3 months (2021-10-17) N/A
6 months (2021-07-21) -55.32%
1 year (2021-01-21) -60.38%
2 years (2020-01-21) -41.94%
3 years (2019-01-17) N/A
5 years (2017-01-17) N/A

Mereo BioPharma Group financials

Revenue TTM $36.5 million
Gross profit TTM $0
Return on assets TTM -10.35%
Return on equity TTM -51.32%
Profit margin -73.83%
Book value $0.82
Market capitalisation $155.7 million

TTM: trailing 12 months

Mereo BioPharma Group share dividends

We're not expecting Mereo BioPharma Group to pay a dividend over the next 12 months.

Mereo BioPharma Group share price volatility

Over the last 12 months, Mereo BioPharma Group's shares have ranged in value from as little as $1.27 up to $4.711. A popular way to gauge a stock's volatility is its "beta".

MREO.US volatility(beta: 1.44)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Mereo BioPharma Group's is 1.4419. This would suggest that Mereo BioPharma Group's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Mereo BioPharma Group overview

Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was founded in 2015 and is based in London, the United Kingdom. .

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site